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Preoperative breast biopsy might cause disaggregation of tumour cells and tumour cell spread. The purpose of this study was to
investigate the impact of preoperative biopsy on the rate of metastases to the sentinel lymph node (SLN) of patients with primary
breast cancer. We report the results of 2502 patients with primary breast cancer, who were operated, and a sentinel node biopsy
was performed. The association of preoperative biopsy with the risk of SLN metastases was examined by regression analyses and
tested for possible confounding well-known factors for axillary node metastases. In all, 1890 patients were available for final analyses;
1048 (55.4%) patients had a preoperative diagnosis performed by fine-needle aspiration or core biopsy; 641 (33.9%) patients had a
positive SLN when conventional H&E and IHC staining was performed. Patients with preoperative breast biopsy showed a 1.37 times
(95% CI, 1.13–1.66) increased risk of SLN metastases on univariate analysis, but this result was not persistent when analysis was
adjusted for other relevant factors for axillary node metastases, OR 1.09 (95% CI, 0.85–1.40). In addition, subgroup analyses of the
risk for occult micro metastases to the SLN (detected by IHC only) on H&E-negative cases also showed no increased risk associated
with preoperative biopsy, OR 1.07 (95% CI, 0.69–1.65). The conclusion, based on the present data, is that preoperative breast
biopsy does not cause artificial tumour cell spread to the SLN, with possible negative impact on the prognosis of breast cancer.
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Modern surgical treatment for breast tumours requires a
preoperative diagnosis of malignancy (Perry, 2001). Fine-needle
aspiration and core biopsy are widely used for evaluation of
palpable and nonpalpable suspicious breast lesions. However,
there has been serious concern about malignant tumour cell
displacement promoting iatrogenic tumour spread. Tumour cell
displacement rates to the needle tract of up to 30% have been
reported (Youngson et al, 1995; Diaz et al, 1999). In theory,
tumour seeding into lymphatic or vascular vessels would carry the
same risk of axillary lymph node metastases as true lymphatic
invasion. To our knowledge, no study has investigated the rate of
breast cancer cell seeding to the axillary nodes for fine-eedle
aspiration and large gauge needle biopsy procedures. The concept
of sentinel lymphadenectomy has been demonstrated to be an
accurate staging alternative for breast cancer (Krag et al, 1993,
1998; Giuliano et al, 1994, 1997; Veronesi et al, 1997; Veronesi et al,
2003). The sentinel node (SLN) is as per definition ‘the first lymph
node that receives afferent lymphatic drainage from a primary
tumour’. With the thorough pathologic examination of the SLN, it
is possible to detect even early tumour cell spread in a lymph node,
which might not have been seen otherwise. The previous analysis
carried out by the Austrian Sentinel Node Biopsy Study Group
revealed a nonsignificant trend of an increased risk of SLN
metastasis after preoperative breast biopsy (Pichler-Gebhard et al,
2002). The purpose of this study was to evaluate the impact of
preoperative biopsy on the rate of metastasis to the SLN of patients
with primary breast cancer.
MATERIALS AND METHODS
Patients and data collection
A total of 2502 consecutive women with primary breast cancer, in
whom a SLN procedure was performed, were registered by the
multi-centre database project (MCDBP) (Konstantiniuk et al,
2001). Patient data from 12 participating departments of the
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lAustrian Sentinel Node Biopsy Study Group were collected
prospectively from 1999 onwards, but data from some centres
were obtained retrospectively from 1996 onwards. Feasibility and
validation of the SLN biopsy method of the participating centres
have been demonstrated by the Austrian Sentinel Node Biopsy
Study Group previously. Each participating centre had to undergo
a learning period, as has been established by means of quality
control (Pichler-Gebhard et al, 2002). In all, 2328 cases remained
after excluding women having received preoperative systemic
treatment, patients with multifocal disease and in situ carcinomas
as the role of SLN biopsy method in this group of patients still
needs to be defined.
Treatment methods
Biopsy procedures of palpable masses were carried out by fine-
needle aspiration or automated gun, nonpalpable masses, either by
sonographically or by stereotactically guided biopsy. The number
of FNA or core specimens obtained was at the discretion of the
examiner performing the procedure. In cases of nonpalpable
lesions, a stereotactic or ultrasound-guided wire localisation of the
tumour was performed preoperatively. Lymphatic mapping and
SLN dissection (SLND) were performed by using blue dye or
radiolabelled colloid, or a combination of both. Blue dye and
colloid were injected either around the edge of the lesion or
submammillarily. If an excisional biopsy had to be performed for
the diagnosis of malignancy, confirmation by the use of frozen
section was followed by immediate SLND in the majority of cases.
Sentinel lymph node dissection was performed as a second
procedure if a permanent section of the excision specimen
revealed invasive tumour in frozen section-negative cases or when
frozen section was not available. In patients with preoperative
diagnosis of malignancy by core needle biopsy, SLND was
performed upfront. Sentinel nodes were dissected and sent for
frozen section. Standard surgical treatment with quadrantectomy
or total mastectomy was completed. Axillary lymph node
dissection was performed if frozen section of the SLN identified
tumour cells. Tumours were classified as described by the
American Joint Committee on Cancer. Sentinel nodes were
examined at two-step section levels of the paraffin block separated
by 250mm. One of every pair was stained at each level by H&E and
followed by cytokeratin IHC staining with monoclonal anti-
cytokeratin antibodies if the H&E sections did not reveal
metastases. Every second corresponding slide was further stained
with IHC (Rudas et al, 2002).
Statistical analyses
Continuous variables were compared by Student’s t-test. For
comparison of categorical variables, the w
2 test was used. Risk
estimates were carried out by univariate and multivariate logistic
regression analysis. All reported P-values are results of two-sided
tests. A P-value equal to or less than 5% was considered
statistically significant. The SPSS 10.0.7 statistical software system
was used for calculations.
RESULTS
In 2079 out of 2328 patients a SLN was found, resulting in an
overall identification rate of 89.3% (not stratified according to
learning period). Finally, we had 1890 patients aged between 23
and 96 years (median age, 60 years) with complete information on
all data evaluable for analyses. In all, 230 (12.1%) patients had a
preoperative diagnosis carried out by FNA, 818 (43.3%) by core
biopsy vs 842 (44.6%) patients without preoperative biopsy.
Patients’ clinicopathological characteristics are listed in Table 1.
Patients undergoing a preoperative biopsy had larger (mean
difference 2.87mm) and more palpable tumours than the control
group. This might be due to the nonavailability of stereotactic
procedure in some participating centres. Lymphatic mapping
Table 1 Patients characteristics
No biopsy Biopsy
N¼842 N¼1048 P-value
Age (years,
mean, s.d.)
60.4 (13.0) 59.7 (12.9) 0.242
Tumour size
(mm, mean,
s.d., range)
14.9 (s.d. 8.1, 1.0–75) 17.8 (s.d. 8.9, 0.5–80) o0.0001
Tumour location 0.351
Inner upper 100 (11.9%) 140 (13.4%)
Inner lower 54 (6.4%) 61 (5.8%)
Outer upper 464 (55.1%) 604 (57.6%)
Outer lower 135 (16.0%) 155 (14.8%)
Central 89 (10.6%) 88 (8.4%)
Histologic type 0.006
Ductal 526 (62.5%) 704 (67.2%)
Lobular 97 (11.5%) 138 (13.2%)
Ducto-
lobular
90 (10.7%) 73 (7.0%)
Other 129 (15.3%) 133 (12.7%)
Grading 0.055
GI 149 (17.7%) 144 (13.7%)
GII 439 (52.1%) 562 (53.6%)
GIII 254 (30.2) 342 (32.6)
Learning period o0.0001
Yes 237 (28.1%) 177 (16.9%)
No 607 (71.9%) 871 (83.1%)
Palpable o0.0001
No 352 (41.8%) 268 (25.6%)
Yes 490 (58.2%) 780 (74.4%)
Department o0.0001
1 75 (8.9%) 177 (16.9%)
2 40 (4.8%) 72 (6.9%)
3 229 (27.2%) 143 (13.6%)
4 188 (22.3%) 95 (9.0%)
5 137 (16.3%) 338 (32.2%)
6 63 (7.5%) 1 (0.1%)
7 13 (1.5%) 55 (5.2%)
8 40 (4.8%) 103 (9.8%)
9 14 (1.7%) 30 (2.8%)
10 10 (1.2%) 19 (1.8%)
11 0 (0.0%) 13 (1.2%)
12 33 (3.9%) 2 (0.2%)
SLN technique o0.0001
Blue dye 317 (37.6%) 184 (17.6%)
Radioisotope 243 (28.9%) 146 (13.9%)
Combination 282 (33.5%) 718 (68.5%)
Table 2 SLN positivity according to biopsy and histological workup
No biopsy Biopsy FNA
Core
biopsy
N¼842 N¼1048 N¼230 N¼818
SLN positivity
(HE+IHC)
253 (30.0%) 388 (37.0%) 78 (33.9%) 310 (37.9%)
SLN positivity (HE) 213 (25.3%) 340 (32.4%) 73 (31.7%) 267 (32.6%)
SLN positivity (IHC) 40 (4.7%) 48 (4.6%) 5 (2.2%) 43 (5.3%)
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We found more ductal and lobular carcinomas and less ducto-
lobular and other subtypes in the biopsy group. Tumour grading
was nearly evenly distributed; patients’ age and tumour location
were comparable between both groups. Overall, 7.4% of the
patients had SLND performed as a second procedure (3.1% in the
biopsy group vs 12.8% in the nonbiopsy group).
Sentinel lymph node metastases were detected in 641 (33.9%)
of 1890 patients. In all, 388 (37.0%) positive SLN were observed
in the preoperative biopsy group and 253 (30.0%) in the
control group. A total of 553 (29.3%) patients had a positive SLN
when conventional H&E staining was performed. In 88 (4.6%)
patients the presence of metastases was detected by IHC only
(Table 2).
Table 3 Association between SLN metastases and clinicopathologic factors by univariate and multivariate analysis
Univariate Multivariate
N % SLN positive Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Age (years) 0.98 0.98–0.99 0.002 0.98 0.97–0.99 o0.0001
Tumour size (mm) 1.07 1.06–1.09 o0.0001 1.06 1.05–1.08 o0.0001
Histology o0.0001 0.0004
Ductal 1230 33 1.00 1.00
Ducto-lobular 163 49 1.97 1.42–2.74 o0.0001 2.16 1.48–3.16 0.0001
Lobular 235 39 1.29 0.97–1.72 0.081 1.12 0.82–1.54 0.487
Others 262 25 0.68 0.51–0.93 0.016 0.82 0.58–1.16 0.246
Grading o0.0001 0.0003
I 293 18 0.34 0.24–0.48 o0.0001 0.55 0.32–0.81 0.002
II 1001 36 0.89 0.72–1.10 0.275 1.17 0.93–1.48 0.177
III 596 39 1.00 1.00
Location 0.710 0.310
Inner upper 240 30 1.00 1.00
Inner lower 115 29 0.96 0.59–1.56 0.863 1.09 0.65–1.84 0.738
Outer upper 1068 33 1.19 0.88–1.62 0.252 1.26 0.91–1.76 0.165
Outer lower 290 38 1.43 0.99–2.06 0.053 1.49 1.01–2.22 0.044
Central 177 40 1.59 1.06–2.40 0.025 1.39 0.89–2.17 0.151
Palpability
Palpable 1270 41 2.78 2.22–3.49 o0.0001 1.77 1.37–2.29 o0.0001
Not palpable 620 20 1.00 1.00
Preop-biopsy
No 842 30 1.000 1.00
Yes 1048 37 1.37 1.13–1.66 0.001 1.09 0.85–1.40 0.508
Learning period
No 1476 34 0.95 0.76–1.20 0.673 1.13 0.79–1.62 0.509
Yes 414 35 1.00
Department 0.003 0.001
1 252 37 1.00 1.00
2 112 42 1.24 0.78–1.95 0.360 1.75 1.04–2.95 0.036
3 372 29 0.71 0.50–0.99 0.047 0.75 0.50–1.12 0.157
4 283 41 1.20 0.85–1.71 0.294 0.75 0.47–1.18 0.210
5 475 28 0.66 0.48–0.92 0.014 0.56 0.38–0.83 0.004
6 64 33 0.83 0.47–1.49 0.543 0.52 0.24–1.09 0.084
7 68 32 0.82 0.46–1.44 0.488 0.74 0.39–1.40 0.354
8 143 43 1.27 0.84–1.93 0.260 1.35 0.84–2.16 0.216
9 44 36 0.98 0.50–1.90 0.945 1.02 0.45–2.30 0.958
10 29 34 0.90 0.40–2.02 0.798 0.88 0.3–2.32 0.795
11 13 31 0.76 0.23–2.54 0.655 0.74 0.20–2.81 0.664
12 35 25 0.51 0.22–1.16 0.108 0.49 0.19–1.29 0.150
SLN technique 0.087 0.175
Combination 1000 33.5 1.00
Blue dye 501 38 1.27 1.01–1.59 0.037 1.20 0.86–1.68 0.287
Radiotracer 389 32 0.99 0.77–1.28 0.969 1.35 0.96–1.90 0.083
SLN timing
1st procedure 1750 35 1.00 1.00
2nd procedure 140 23 0.59 0.39–0.87 0.008 1.01 0.63–1.62 0.969
Study period
Prospective 1354 34 1.00 1.00
Retrospective 536 35 1.06 0.86–1.31 0.574 0.97 0.70–1.38 0.848
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IHC staining), univariate regression analysis identified larger
tumour size (Po0.0001), age (P¼0.002), preoperative biopsy
(P¼0.001), histological type (Po0.0001), grading (Po0.0001),
palpability of the lesion (Po0.0001), timing of SLN biopsy
(P¼0.008) and participating centre (P¼0.003) as significant
factors. Preoperative biopsy revealed a hazard ratio of 1.37 (95%
CI, 1.13–1.66). Finally, all factors were entered in a multivariate
regression model. The impact of each of the evaluated factors is
shown in Table 3. Of the variables which showed a significant
correlation with SLN positivity in the univariate analysis, tumour
size, tumour grading, histological type, age, palpability and
participating centre remained as independent predictors for SLN
metastasis, whereas preoperative biopsy failed to show significance.
Patients with preoperative breast biopsy had a nonsignificant 1.09-
fold (95% CI, 0.85–1.40) increased risk for SLN metastases.
As seeding to the needle tract during FNA is a very rare event,
patients with preoperative FNA might have a different rate of
tumour cell seeding than patients with large-gauge needle biopsy
(Roussel and Dalion, 1989; Tabara et al, 1991; Bott et al, 1999).
Therefore, further analysis was carried out with FNA and core
biopsy as separate categories. Univariate analysis showed a
significant correlation with SLN positivity for core biopsy, OR
1.42 (95% CI, 1.16–1.74), whereas no impact for FNA RR 1.19
(95% CI, 0.88–1.63) was found. However, when analysis was
adjusted for other relevant factors for axillary node metastasis,
preoperative biopsy again failed to show significance, OR 1.10
(95% CI, 0.85–1.43) and OR 1.03 (95% CI, 0.69–1.53), respectively.
In addition, subgroup analysis of the risk for occult micro-
metastases to the SLN (detected by IHC only) on H&E-negative
cases with additional IHC staining also failed to show an increased
risk for preoperative biopsy, OR 1.07 (95% CI, 0.69–1.65).
DISCUSSION
This study examined the risk of SLN metastases in patients who
underwent prior FNA or large-gauge needle core biopsy. Our results
do not confirm the findings of a recently published study,
performed on a much smaller number of patients (Hansen et al,
2004), suggesting a positive association between needle biopsy and
SLN metastases. Studies of SLN metastases must take into account
all well-known predictive factors for axillary node metastases such
as tumour size, clinical and histo-pathological criteria. The
significant result of an increased risk for SLN metastases after
preoperative biopsy obtained on univariate calculation was no
longer present when adjustment for relevant predictors for axillary
node metastases was done by means of multivariate analysis. The
additional use of IHC for further evaluation of the SLN increases the
detection of occult micro-metastases and improves the sensitivity of
the SLN procedure (Czerniecki et al,1 9 9 9 ) .W ef o u n da6 . 5 %
conversion rate of H&E-negative patients to lymph node positive in
our series. Nevertheless, patients who underwent a preoperative
biopsy had no increased risk for a SLN metastases detected by H&E
and IHC or IHC alone. Large tumours were more likely to have
nodal involvement than smaller tumours; this is in agreement with
other findings (Gann et al, 1999). Clinical palpability remains to be
highly predictive for SLN metastases, as has been demonstrated by
other authors (Silverstein et al, 2001). In addition to our previous
findings, we found high-grade lesions and age to be associated with
higher rate of metastases, which is in accordance with other studies
(Gann et al, 1999). Infiltrating ducto-lobular carcinomas had higher
rates of SLN metastasis than other types; this confirmed the
surprising findings of our first analysis.
Without any doubt, the rate of metastases to the sentinel node
can be affected by several factors. In order to objectify this study as
far as possible, we identified five possibilities of biases, which may
have adversely affected the accuracy of our risk assessment.
Firstly, no data on failure of preoperative core biopsy were
available in our series. A negative core biopsy would increase the
number of cases in the nonbiopsy group, altering the result in
favour of a positive impact of the biopsy procedure. Nevertheless,
assuming a failure rate of less than 10% would not change our
results. Secondly, SLN identification by using blue dye alone might
result in a higher false negative and lower detection rate. However,
this point was considered and technique of SLN identification was
included in the analysis. Thirdly, preoperative hook wire localisa-
tion procedure of nonpalpable breast lesions might also cause
disintegration of tumours (Fajardo, 1988). To overcome this bias,
clinical palpability of the breast lesion was included in the
multivariate model. The fourth point is we must emphasise that
there were no data on the time interval between the preoperative
biopsy procedure and the SLND available in our study. Assuming a
decreased incidence of local tumour displacement at increasing
intervals between core biopsy and excision, as suggested by other
authors (Diaz et al, 1999), the impact of the time interval should
bias the study in favour of an increased risk for the occurrence of
occult SLN metastasis following preoperative biopsy. In addition,
the timing of SLND following excision biopsy was identified as a
possible confounding factor. And, finally, surgical resection itself
might have an impact on tumour cell displacement and tumour
cell spread. Previous studies carried out on a small number of
patients revealed that manipulation during cancer surgery in
human beings might result in tumour cell dissemination into the
vascular circulation (Choy and McCulloch, 1996). Excisional
biopsy was only performed prior to SLND in patients without
preoperative diagnosis of malignancy (non-core biopsy group and
patients with negative core biopsy). Assuming additional tumour
cell shedding into the lymphatic system will further enhance the
impact of preoperative biopsy. This point remains unclear and
needs further investigation. We are indeed aware of these possible
biases and the retrospective nature of the study while interpreting
our data, but considering the large patient population and the
power of multivariate analyses the overall impact of the above-
mentioned concerns does not alter our results.
The present data clearly indicate that preoperative biopsy does
not increase the risk of metastases to the SLN in patients suffering
from breast cancer. There is no evidence for any tumour cell
spread to the sentinel node with possible negative impact on the
prognosis of breast cancer. In conclusion, preoperative breast
biopsy is a safe method and should be used to achieve definitive
diagnosis of malignant breast lesions.
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